Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
This research aims to compare the effects of a single injection of platelet-rich plasma PRP versus conditioned serum CS in the knee joints of patients with early-stage bilateral knee osteoarthritis grades 1 or 2. The study evaluates these two autologous treatments by monitoring various serum markers and physical function outcomes to understand their impact on the condition. Participants are divided into two groups one receives a single dose injection of autologous PRP, and the other receives an equivalent volume of autologous conditioned serum also known as activated cytokine-rich serum. Blood samples are collected before injection, 30 minutes after, and at one week and one month to analyze inflammatory and growth factor markers. Treatments are delivered directly into the knee joint. Throughout the study, participants are assessed at one week, one month, and three months after injection. Evaluations include visual pain scale scores, Western Ontario and McMaster Universities Osteoarthritis Index WOMAC scores, range of motion, ultrasound measurements of cartilage thickness, and multiple functional tests such as chair stands, stair climbing, walking speed, and timed up and go. These assessments help measure treatment effects on pain, function, and joint health over time.
Actively Recruiting
Researchers are evaluating Datopotamab Deruxtecan Dato-DXd alone and combined with other anticancer drugs in patients with advanced or metastatic solid tumors. This Phase II, open-label, multicenter study uses a modular master protocol to assess safety, tolerability, recommended dosing, and effectiveness across several cancer types including endometrial, gastric, prostate, ovarian, colorectal, urothelial, and biliary tract cancers. The study allows simultaneous evaluation of Dato-DXd in various treatment combinations and disease settings. Participants receive Dato-DXd intravenously as monotherapy or combined with approved or novel anticancer agents, varying by cancer subtype. Treatment combinations include capecitabine, 5-Fluorouracil, prednisoneprednisolone, carboplatin, bevacizumab, volrustomig, rilvegostomig, and cisplatin. Each substudy tests either monotherapy or combination therapy tailored to the tumor type. The study follows participants during treatment and a safety follow-up period, with some treatments administered orally or intravenously depending on the agent. Throughout the approximately one-year study period, participants undergo regular assessments including tumor measurement, adverse event monitoring, pharmacokinetic sampling, and specific biomarker evaluations such as PSA, CA-125, and radiographic progression depending on cancer type. Researchers evaluate outcomes like objective response rate, progression-free survival, disease control, and overall survival. Safety is monitored closely during and up to 28 or 90 days after treatment discontinuation. Participants provide tumor samples for tissue analysis and may consent to optional genetic research.